Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Monte Rosa Therapeutics Inc GLUE

Healthcare Biotechnology
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GLUE)

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

GlobeNewswire 1 day ago

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire November 13, 2024

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2024

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire October 28, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

GlobeNewswire October 23, 2024

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

GlobeNewswire August 19, 2024

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2024

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

GlobeNewswire July 8, 2024
View More News ››

Opinion & Analysis (NDAQ:GLUE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GLUE)

The MoBot Report

Just In: $GLUE The MoBot Report2024-10-28 12:33:06 ET DENVER, Colo., Oct 28, 2024 ( 247marketnews.com )- MoBot@s recent alerts involved;...
whytestocks - October 28, 2024

Monte Rosa Therapeutics' AI And Machine Learning Platform Is

NEWS: $GLUE Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research...
whytestocks - February 15, 2024
View more Bullboard ››

Vanstar Mining Resources Inc.

Vanstar Mining Resources Inc.

Vanstar Mining’s Nelligan gold project joint venture with IAMGOLD (25% VSR/75% IMG), located 60 kilometres SW of Chibougamau, ...
View More »